After hitting new all-time highs in 2023, the S&P 500 is off to a slower start this year. The broad-based index is down 1.5% in the first week of trading. The first jobs report of the new year showed strong gains, which could cause the Federal Reserve to stand firm on the high interest rates it jacked up last year. That could make for a slower-growing economy in 2024. This backdrop has led to the stock picks to buy.But no one knows which way it will really go so it’s best not to try and time. Same with the ...

DaVita Inc. (NYSE:DVA) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Jeffrey Giullian - Chief Medical Officer Conference Call Participants Pito Chickering - Deutsche Bank Justin Lake - Wolfe Research Kevin Fischbeck - Bank of America Lisa Clive - Bernstein Operator Good evening. My name is Jordan, and I will be your conference facilitat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. Delaware 51-0354549 (State of incorporation) (I.R.S. Employer Identification No.) 2000 16th St ...

DaVita Inc. (NYSE:DVA) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Joanna Gajuk - Bank of America Andrew Mok - UBS Pito Chickering - Deutsche Bank Lisa Clive - Bernstein Operator Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. Delaware 51-0354549 (State of incorporation) (I.R.S. Employer Identification No.) 2000 16th Street ...

Financial Performance - In Q1, the company reported adjusted operating income of $352 million and adjusted earnings per share of $1.58, reflecting positive results from initiatives implemented in late 2022 to address lower volumes and higher costs [5][19] - Free cash flow for the quarter was $265 million, indicating strong cash generation [19] - On a non-GAAP basis, patient care cost per treatment decreased by $1.18 sequentially, driven by pharmaceutical cost savings and reductions in contract labor spend [9] Treatment Volume and Business Lines - Treatments per day increased approximately 1% quarter-over-quarter, attributed to net census gains from higher admissions and lower mortality [6][38] - The company anticipates a year-over-year reduction in overall treatment volume due to excess mortality from 2022, but expects to finish the year in the top half of the volume forecast range of down 3% to flat relative to 2022 [6] - The Integrated Kidney Care (IKC) program saw over half of its patients achieve an optimal start, which reduces hospitalizations and costs [7] Market and Operational Metrics - U.S. dialysis treatments per day were up almost 1% compared to Q4, driven by higher patient census, while mistreatment rates remained elevated compared to pre-COVID levels [38][44] - Revenue per treatment decreased by $0.16 quarter-over-quarter due to seasonal impacts and increased patient responsibility [38] Company Strategy and Industry Competition - The company is focused on connecting transitions of care through solutions for patients across the kidney care continuum, with a strong emphasis on CKD education [4] - DaVita launched Mozarc Medical in partnership with Medtronic, aimed at innovating kidney health technologies, which reflects the company's commitment to transforming kidney care [80] - The company plans to consolidate an additional 40 to 50 centers over the remainder of the year, which is expected to enhance operational efficiency [21] Management Commentary on Operating Environment and Future Outlook - Management expressed cautious optimism about executing their plan amid uncertainties in treatment volume and labor market challenges [17] - The company expects continued wage pressure throughout the year, with a projected increase in labor costs [25][102] - Management revised the adjusted operating income range for the year to $1.475 billion to $1.625 billion, indicating confidence in achieving strong results [95] Other Important Information - The company is on track to realize year-over-year savings of $125 million to $175 million, primarily driven by cost-saving initiatives [10] - The company anticipates a negative impact on other income of $15 million per quarter for the remainder of the year [39] Q&A Session Summary Question: What are the underlying drivers of the treatment growth beat in the quarter? - Management noted that treatment per day was up about 90 basis points quarter-over-quarter, driven by census increases from admissions offset by continued excess mortality [28] Question: Can you provide an update on the ESA switch to Mircera? - Management confirmed that the rollout is proceeding as planned and clinical results are meeting expectations, although no specific KPIs were disclosed [46] Question: What is the expected impact of labor costs for the rest of the year? - Management indicated that they are about $25 million ahead of previous labor cost expectations, with half attributed to labor and half to volume improvements [24] Question: How is the IKC program tracking against previous guidance? - Management stated that while the IKC program is growing, it remains in the investment phase, and they expect to be breakeven by 2026 [50] Question: What is the current status of excess mortality? - Management reported that excess mortality was about 900 patients in the quarter, with expectations adjusted to between 2,500 and 3,000 patients for the remainder of the year [65]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 51-0354549 (State of incorporation) (I.R.S. Employer Identification No.) 2000 16th Street Denver, CO 80202 Telephone number (720) 631-2100 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

DaVita, Inc. (NYSE:DVA) Q4 2022 Earnings Conference Call February 22, 2023 5:00 PM ET Company Participants Javier Rodriguez - CEO & Executive Director Joel Ackerman - CFO & Treasurer Conference Call Participants Andrew Mok - UBS Philip Chickering - Deutsche Bank Gary Taylor - Cowen and Company Kevin Fischbeck - Bank of America Merrill Lynch Operator Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita Fourth Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. (Exact name of registrant as specified in charter) Delaware 51-0354549 (State of incorporation) (I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 1-14106 DAVITA INC. Delaware 51-0354549 (State of incorporation) (I.R.S. Employer Identification No.) 2000 16th St ...